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a b s t r a c t
Monkeypox virus (MPXV) is an emerging pathogen from Africa that causes disease similar to smallpox.
Two clades with different geographic distributions and virulence have been described. Here, we utilized
bioinformatic tools to identify genomic regions in MPXV containing multiple virulence genes and
explored their roles in pathogenicity; two selected regions were then deleted singularly or in
combination. In vitro and in vivo studies indicated that these regions play a signiﬁcant role in MPXV
replication, tissue spread, and mortality in mice. Interestingly, while deletion of either region led to
decreased virulence in mice, one region had no effect on in vitro replication. Deletion of both regions
simultaneously also reduced cell culture replication and signiﬁcantly increased the attenuation in vivo
over either single deletion. Attenuated MPXV with genomic deletions present a safe and efﬁcacious tool
in the study of MPX pathogenesis and in the identiﬁcation of genetic factors associated with virulence.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Monkeypox virus (MPXV; Poxviridae, Orthopoxvirus) causes
human monkeypox (MPX), a disease with a clinical presentation
that resembles human smallpox (Cann et al., 2013; Huhn et al.,
2005). Human MPX is endemic in equatorial Africa, and no speciﬁc
wild animal reservoir has been identiﬁed. Recent epidemiologic
studies have shown an increase in human MPX cases in the last 30
years in the central region of Africa (Reynolds and Damon, 2012;
Rimoin et al., 2010). In 2003, the virus was introduced to the
United States through the importation of infected rodents from
West Africa (Likos et al., 2005; Reynolds and Damon, 2012). In
2005, human MPX cases were identiﬁed in southern Sudan (now
South Sudan), and are thought to be associated with translocations
of infected humans or animals from Central Africa (Nakazawa
et al., 2013).
The emergence of MPXV, as well as its potential threat as a
bioterrorism weapon, warrants the study of its mechanisms of
infection, virulence factors, and pathogenesis (Breman and
Henderson, 1998; Reynolds and Damon, 2012; Rimoin et al.,
2010). Genomic comparisons of MPXV human isolates have
revealed the existence of two highly diverse clades of MPXV with
different geographic distribution and pathogenicity. Infections
with MPXVs isolated from Central Africa (MPXV/Congo) cause
more severe disease in humans and rodents compared to viruses
in the West African clade (MPXV/USA) (Chen et al., 2005; Hutson
and Damon, 2010; Likos et al., 2005). Comparisons between these
MPXV clades and related orthopoxvirus (OPXV) genomes have
shown that although these are closely related viruses, they contain
several highly variable genomic regions (termed here regions [R])
that are characterized by high mutation rates, insertions, dele-
tions, and gene truncations (Chen et al., 2005; Hendrickson et al.,
2010; Shchelkunov et al., 2001). In MPXV and other OPXVs these
regions contain several known host range and immunomodulatory
(IMM) genes (Seet et al., 2003). These genes have evolved
speciﬁcally to simultaneously inhibit diverse processes such as
pattern-recognition receptor signaling, apoptosis, chemokine and
cytokine function, and lymphocyte and antibody activity
(Fernandez de Marco Mdel et al., 2010; Hammarlund et al.,
2008; Kindrachuk et al., 2012; Weaver and Isaacs, 2008). Whereas
previous evaluations of MPXV virulence factors have predomi-
nantly focused on the function and characterization of individual
viral genes, these studies demonstrated that individual genes were
not solely responsible for the observed differences in pathogeni-
city between MPXV clades (Estep et al., 2011; Hudson et al., 2012).
In contrast, we evaluated the effect of deletions of large genomic
regions in MPXV that contain several host range and IMM genes to
facilitate selection of candidate virulence factors involved in
pathogenesis. Speciﬁcally, we quantiﬁed and compared the effect
of deletion of two genomic regions in a Central African MPXV-
Congo strain. The impacts of these deletions on replication
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kinetics, host immune response, host tissue tropism and virulence
were analyzed using cell culture, immunoassays and in vivo
imaging. The research described herein identiﬁed regions in the
MPXV genome that can inform the selection of candidate genes for
future study to more fully dissect the molecular determinants of
virulence in MPXV.
Results
Identiﬁcation of genomic regions and generation of recombinant
viruses
Genomic alignments and sequence comparisons between
MPXV clades and other related OPXV helped to identify two target
genomic regions (R) located at the 50 and 30 ends of the genomes
(Fig. 1). Sequences of MPXVs and related OPXVs were obtained
from Genbank (GB: DQ011157, DQ011154, NC001611, NC006998
and AY603355) and analyzed using bioinformatic tools. Genomic
regions were selected based on mutation rates and presence of
large-scale evolutionary events such as genomic rearrangement,
inversion, truncation, insertion, and deletion. Additionally, each
genomic region was selected by its degree of divergence between
related viruses and its density of known virulence genes (Fig. 1 and
Table 1). Through this analysis, two genomic regions were selected
for in-depth analysis (Fig. 1). Three recombinant viruses (MPXV-
ΔR1, MPXV-ΔR2, and MPXV-ΔR1/R2) containing deletions of
individual or combined genomic regions were constructed (Fig. 2).
Recombinant viruses were plaque puriﬁed, titered and assayed by
cell culture and in vivo imaging.
Deletion of genomic regions in MPXV affected the replication kinetics
and plaque size in cell culture
One-step growth curves and plaque size measurements were
used to evaluate whether the deletion of genomic regions in MPXV
affected in vitro growth and other phenotypic characteristics of
gene-deleted viruses. Deletion of target genomic regions in MPXV
reduced the in vitro growth characteristics of two of the recombi-
nant viruses. MPXV-ΔR1 and MPXV-ΔR1/R2 viruses showed
signiﬁcant reduction in viral replication and total yield, as well
as cell-to-cell spread. At 24, 48, and 72 h post-infection (pi),
MPXV-ΔR1 and MPXV-ΔR1/R2 replicated to signiﬁcantly lower
peak titers (po0.001) and formed signiﬁcantly smaller mean
plaque sizes (po0.01) as compared to parental MPXV-Congo/
Lucþ (Fig. 3A and B respectively). Interestingly, for MPXV-ΔR2
virus, the growth kinetics in cell culture appeared normal and
comparable to parental MPXV-Congo/Lucþ . The lag and rise
periods of exponential growth curves were of similar duration
along with peak titers (Fig. 3A). In addition, MPXV-ΔR2 virus did
not differ in plaque size when compared to the parental MPXV-
Congo/Lucþ (Fig. 3B). One-step growth curves in A549 cells
showed similar results to Vero cells; however no differences in
plaque phenotype were observed between parental and gene-
deleted MPXVs (data not shown).
In vivo imaging demonstrated MPXV attenuation by deletion of
genomic regions
Biophotonic in vivo imaging of CAST/EiJ mice was used to
determine the pathogenicity of MPXV-ΔR1, MPXV-ΔR2, and
MPXV-ΔR1/R2. At day 4 pi, viral spread and increased viral
replication was seen in MPXV-Congo/Lucþ infected mice as
compared to all of the gene-deleted viruses (Figs. 4 and 5A).
Viruses containing deletions did not show signals of viral spread at
day 4 pi. Between day 6 and 8 pi, morbidity, high viral replication,
and generalized viral dissemination were observed in the control
MPXV-Congo/Lucþ group (Figs. 4 and 5). All MPXV-Congo/Lucþ
infected mice died or were euthanized by 8 days pi (Fig. 4). Only
animals infected with parental MPXV-Congo/Lucþ exhibited sig-
niﬁcant weight loss (po0.01) (Fig. 5B). Weight change was not
signiﬁcantly different between groups of mice infected with MPXV
Fig. 1. Sequence comparisons and identiﬁcation of target genomic regions. The colored bars inside the genomic blocks represent the level of sequence similarities between
viruses. Regions with high sequence similarity are shown in light purple. Regions with mutations, insertions, and deletions of genes are represented in colored bars. White
bars represent genomic sequences present in only one viral genome. Boxes surround predicted genomic regions in MPXV clades. Lines link orthologous genomic regions in
MPXV, variola virus (VARV), vaccinia virus (VACV) and modiﬁed vaccinia ankara (MVA) genomes. Genomic regions were selected based upon sequence analysis utilizing
MAUVE and DAMBE software. Regions characterized in this study are indicated by R1 and R2.
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with deletions (Fig. 5B). Signiﬁcant differences (po0.01) in lumi-
nescence were detected between gene-deleted viruses at days 6, 8,
and 10 pi (Figs. 4 and 5A). Luminescent signal peaked on day 6 pi
in mice infected with MPXV-ΔR1 or MPXV-ΔR2 (Figs. 4 and 5A).
Animals infected with the MPXV-ΔR1/R2 showed a signiﬁcant
reduction (po0.001) at days 6 and 8 pi in viral replication and
Table 1
Genes contained in the two MPXV genomic regions and their reported functions.
Deletion aLocation (ORF) bMPXV/
VACV
Function
Region R1 17 D9L/C9L Ankyrin-like
18 D10L/C7L Inhibits type I – IFN signaling (Meng et al., 2009, 2012)
19 D11L/C6L Unknown
20 D12L/C5L BTB domain of VACV C2L gene associated with adhesion and inﬂammation (Pires de Miranda et al., 2003)
21 D13L/C4L Unknown
22 D14L/C3L Regulates complement activation (Hudson et al., 2012; McKenzie et al., 1992)
23–25 D18L/C2L Kelch-like protein: absent or truncated in West African MPXV (Pires de Miranda et al., 2003)
26 D19L/C1L Unknown
27 P1L/N1L Inhibits apoptosis and NF-κB activation (Maluquer de Motes et al., 2011)
28 P2L/N2L α-amanitin-resistant and temperature-sensitive phenotypes (Tamin et al., 1991)
29 O1L/M1L Ankyrin-like
30 O2L/M2L Inhibits NF-ĸB activation via ERK2 signaling (Gedey et al., 2006)
31 C1L/K1L Inhibits NF-ĸB activation preventing IĸBα degradation (Shisler and Jin, 2004)
Region R2 181 B7R/B6R Ankyrin-like
182 B8R/B7R Modulator of virulence (Price et al., 2000)
183 B9R/B8R Soluble INF-gamma receptor-like protein (Verardi et al., 2001)
184 B10R/B9R Host defense modulator (Price et al., 2002)
185 /B11R Unknown
186 B11R/B12R Ser/thr protein kinase-like similar to VACV B1R gene an apoptosis inhibitor (Banham and Smith, 1993; Santos et al., 2006)
187 B12R/B13R Apoptosis inhibidor: SPI-2/crmA, IL-1 convertase (Kettle et al., 1997)
188 B13R/B15R Unknown
189 B14R/B15R Host defense modulator : IL-1beta inhibitor (Alcami and Smith, 1992)
190 B15R/B17L Unknown: absent in West African MPXV
191 /B17L Unknown: absent in West African MPXV
192 B16R/B19R IFN-alpha/beta-receptor-like secreted glycoprotein (Fernandez de Marco Mdel et al., 2010; Gomez et al., 2012)
a Open Reading Frames: GeneBank, DQ011154 (MPXV strain RCG/2003-358).
b Nomenclature from GeneBank sequences DQ011154 and NC006998 (VACV strain Western Reserve).
Fig. 2. Overview of recombination approach used to delete genomic regions in MPXV. The orientation of genes in the MPXV genome and luciferase and selection markers
(GPT and CFP) in the transfer plasmids are noted by arrows. Flanking sequences of genomic regions are represented by rectangular bars. Dashed lines indicate the location of
recombination within the MPXV genome and transfer plasmid in each genomic region. GenBank MPXV genomic sequences were utilized to clone the ﬂank regions
(DQ011154). Numbers indicate the corresponding open reading frames (ORFs) in the reference sequence. Locations of the primers used are represented by primer number
(P). SnapGenes software (from GSL Biotech; available at snapgene.com) was used to generate the maps of the genomic deletions.
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spread as compared with MPXV-ΔR1 and MPXV-ΔR2, indicating
an additive effect of deletion of genes in both genomic regions
(Figs. 4 and 5A). All the mice infected with gene-deleted viruses
survived infection; after 20 days pi none of the mice had
detectable levels of luminescence and were therefore euthanized.
Real-time PCR and tissue culture of lung and spleen conﬁrmed the
absence of viral DNA and lack of tissue persistence (data not
shown). No differences in end point antibody titers between
MPXV-ΔR1, MPXV-ΔR2, and MPXV-ΔR1/R2 were observed
(Fig. 6A). However, serum of mice infected with MPXV-ΔR1/R2
had lower neutralizing antibody titers when compared with
serum of mice from MPXV-ΔR1 and MPXV-ΔR2 infection
(Fig. 6B).
Histopathology and viral titrations
Tissues were collected at the time of death or euthanasia: 7–8
days pi for the MPXV-Congo/Lucþ and at the completion of the
study (20 days pi) for mice infected with gene-deleted viruses.
Histological examination of spleens from mice infected with
MPXV-Congo/Lucþ showed moderate to severe multifocal to
coalescing lymphoid necrosis (Fig. 7A). Viral inclusions were
occasionally found in active, enlarged macrophages. Virus titers
in spleens of mice infected with MPXV-Congo/Lucþ ranged from
1.68103 to 2.18107 PFU/ml (data not shown). In contrast,
spleens from MPXV-ΔR1 infected mice showed no loss of lym-
phoid cells. Lymphoid hyperplasia was present in spleens from
MPXV-ΔR2 and MPXV-ΔR1/R2 infected mice (Figs. 7C and 7E).
Lungs from MPXV-Congo/Lucþ infected mice showed severe
multifocal lymphoplasmacytic pneumonia (Fig. 7B) with virus
titers that ranged from 4.35106 to 2.57107 PFU/ml (data not
shown). More severely affected animals showed severe necrosis in
a peri-bronchiolar pattern, with ﬁbrin ﬁlling some bronchioles and
many alveoli. Lung tissue sections from mice infected with the
MPXV containing region deletions had very mild lymphoplasma-
cytic inﬁltrates in all three groups (Fig. 7D). MPXV was not
detected by either real-time PCR or tissue culture isolation from
lung and spleen homogenates of animals infected with gene-
deleted MPXVs (data not shown).
Discussion
Experimental deletion of individual and multiple genes in
OPXV genomes has been used to study virulence factors as well
as to improve the immunogenicity and safety of vaccine vectors
(Dimier et al., 2011; Johnston and McFadden, 2004; Kochneva
et al., 2005). These studies have shown that deletion of individual
genes can either reduce (Johnston and McFadden, 2004; Senkevich
et al., 1994) or enhance (Estep et al., 2011; Ng et al., 2001)
replication and virulence. Previous studies that investigated differ-
ences in virulence of MPXV strains have predominantly focused on
the function and characterization of individual genes, for example,
the inhibitor of complement-binding protein (MOPICE), an impor-
tant anti-inﬂammatory factor of OPXV (Estep et al., 2011; Hudson
et al., 2012). The gene that codes for these enzymes (D14R) is
absent in the less virulent West African MPXV strains and has been
considered a major virulence factor in Central African MPXV clade
infection (Chen et al., 2005). Results showed that deletion of D14R
in Central African MPXV clade enhanced viral replication in rhesus
macaques (Estep et al., 2011). Another report showed that deletion
of D14R in Central African MPXV clade subtly reduced morbidity
and mortality in prairie dogs, and D14R insertion in West African
MPXV clade only affected minor disease manifestations (Hudson
et al., 2012). Similar to these previous reports, we have observed
that the single deletion of MOPICE gene and B14R gene, an
inhibitor of IL-1β-binding protein, in MPXV/Congo increased viral
replication and spread after intranasal inoculation of CAST/EiJ
and severe combined immunodeﬁciency (SCID) mice, respectively
(Lopera et al., unpublished data). These studies suggested that
D14R or B14R are not the sole virulence factors responsible for
major differences in MPX pathogenesis (Estep et al., 2011; Hudson
et al., 2012).
Here, we used a larger genomic approach to generate MPXV
with deletion of multiple virulence genes in order to evaluate their
roles in viral replication and pathogenicity. We found that single
and double deletion of two speciﬁc genomic regions in a MPXV
strain from Central Africa affected the cell culture phenotype
(MPXV-ΔR1 and MPXV-ΔR1/R2) and reduced morbidity and
mortality in mice (MPXV-ΔR1, MPXV-ΔR2 and MPXV-ΔR1/R2).
Fig. 3. Deletions of genomic regions in MPXV reduce replication and spread in cell
culture. A) One step growth curves for parental virus (MPXV-Congo/Lucþ) and
viruses with single deletions (MPXV-ΔR1 and MPXV-ΔR2) and simultaneous
deletion of both regions (MPXV-ΔR1/R2). Vero cells in 12-well plates were infected
in duplicate with the recombinant viruses at MOI of 5 PFU/cell. Cells from each well
were harvested at 0, 4, 12, 24, 48, and 72 h post-infection (pi). All samples including
pellet and supernatants were titered by 50% tissue culture infective dose (TCID50).
Mean titers are shown at different times. Error bars represent the standard
deviations (SD) of the replicates. B) Plaque size comparisons between control
MPXV-Congo/Lucþ and gene-deleted viruses. Vero cells in 6-well plates were
infected with the indicated viruses, and at 72 h pi cells were ﬁxed and stained. The
diameters of 40 plaques were measured for each virus. Data are expressed as the
mean and SD of plaque diameter. Stars in the ﬁgures represent signiﬁcant
differences (npo0.01 and nnpo0.001) compared to control MPXV-Congo/Lucþ
results.
J.G. Lopera et al. / Virology 475 (2015) 129–138132
All the gene-deleted viruses characterized in this study were
strongly attenuated in vivo, and further in vivo imaging and
histological analysis conﬁrmed the reduction in pathogenesis. It
is possible that the observed attenuation of MPXV-ΔR1 virus
could be explained, in part, by the reduced capacity of this virus
to grow and spread in cell culture, indicating that genes in ΔR1
have important roles in MPXV replication. On the other hand, the
observed in vivo attenuation of deletion from ΔR2 suggests that
this speciﬁc genomic region contains important genes that affect
MPXV pathogenicity. This result is supported by the observation
that growth of MPXV-ΔR2 appeared normal in cell culture but
was strongly attenuated in vivo. Evaluation of the reported func-
tion of genes deleted in ΔR2 showed that they encode for
important immunomodulatory proteins, including secreted inhi-
bitors of type I and type II interferons, an inhibitor of IL-1β, and
two apoptosis modulators (Gomez et al., 2012; Jackson et al., 2005;
Verardi et al., 2001). Finally, the robust attenuation caused by the
deletion of ΔR1/R2, could be explained by both a reduction of the
capacity of the virus to replicate and the ability to evade the early
host immune responses. Thus, mice infected with MPXV-ΔR1/R2
showed reduction in viral replication and by day 8 pi the luciferase
expression was absent, suggesting early viral detection and clear-
ance by the host immune system. This ﬁnding was further
supported by low levels of neutralizing antibodies induced by
the MPXV-ΔR1/R2. Other studies that evaluated large scale dele-
tions of OPXV genomic regions have shown that the deletion of six
genomic regions in vaccinia virus (VACV) (31 open reading frames)
was not sufﬁcient to reduce cell culture replication and mice
virulence of a parental strain (Meisinger-Henschel et al., 2010). It is
surprising that deletion of these large numbers of genes in VACV,
including some known OPXV virulence factors, has only moderate
effects on the viral pathogenicity. Additionally, the deletion of two
to four genomic regions enhanced the virulence in mice compared
to the parental VACV (Meisinger-Henschel et al., 2010).
The evaluation of MPX disease progression by molecular
imaging is an effective approach for the characterization of MPXV
and other OPXV pathogenesis in mice and wild rodents (Americo
et al., 2014; Falendysz et al., 2014; Osorio et al., 2009). Taking
Fig. 4. In vivo imaging of luminescent gene-deleted viruses shows attenuation in CAST/EiJ mice. Ventral views of mice (CAST/EiJ) infected intranasally with 106 PFU of
parental (MPXV-Congo/Lucþ) or gene-deleted MPXVs (MPXV-ΔR1, MPXV-ΔR2, and MPXV-ΔR1/R2) that express ﬁreﬂy luciferase gene marker. Viral replication, course of
infection (in vivo imaging), weight loss, and deaths were recorded in infected animals for 20 days.
J.G. Lopera et al. / Virology 475 (2015) 129–138 133
advantage of the incorporation of the luciferase gene reporter
system, we used in vivo biophotonic imaging to characterize and
compare MPX disease progression and viral replication in a
susceptible CAST/EiJ mouse model. Previous mouse models such
as SCID, Balb/c, A129 and AG129 mice were not useful for the
characterization of MPXV virulence factors (Hutson et al., 2010;
Hutson and Damon, 2010), because these animals do not succumb
to MPXV infection, and differences in mortality and morbidity are
difﬁcult to observe. Our data showed that the CAST/EiJ animal
model is useful for studying MPXV virulence factors, as well as the
host immune response. However, other animal models, such as
prairie dogs, could display clinical signs that more closely repre-
senting MPX disease in humans (Falendysz et al., 2014). Future
studies will use the prairie dog model to study the effects of
deletions on clinical signs and progression of MPX disease in a
more relevant outbred model. Bioinformatic analysis revealed the
presence of other divergent genomic regions and to understand
the relative contribution of multiple genes on MPXV replication
and pathogenicity, additional studies are needed.
Conclusion
In this study we described the construction and characterization
of large scale deletions of genes in MPXV and evaluated their effect
on disease pathogenesis in mice. We conclude that deletion of
individual (ΔR1 and ΔR2) and dual (ΔR1/R2) target genomic
regions in MPXV-Congo affect viral replication and/or pathogeni-
city. Deletion of R1 affected viral replication, whereas deletion of R2
had a more marked effect on disease pathogenesis. The marked
attenuation of viruses with simultaneous deletion of two regions
(MPXV-ΔR1/R2) illustrates the additive effect of deletion of geno-
mic regions in viral replication and pathogenicity. The mechanisms
by which multiple genes modulate host pathogenesis and immune
response have not been evaluated, and we will further characterize
the additive function of these genes in MPXV infection. Collectively,
our results strongly suggest that the use of parental and mutant
deleted MPXV/Lucþ can be a safe and useful tool with several
potential advantages for the study of MPX pathogenesis.
Fig. 5. Deletions of genomic regions in MPXV reduce morbidity and viral replica-
tion in CAST/EiJ mice. A) Mean and SD of luminescence measurements by time after
infection. B) Mean and SD of weight change of mice in each experimental group
collected at different times after the infection. Stars in the ﬁgures represent
signiﬁcant differences (npo0.01 and nnpo0.001) compared to control MPXV-
Congo/Lucþ results.
Fig. 6. Comparison of humoral responses. A) Serological analysis of CAST/EiJ mice
infected with gene-deleted viruses shows similar antibody titers. Titers of binding
antibodies against MPXV were determined by ELISAs using anti-OPXV immuno-
globulin types A and G. B) Percent of neutralizing activity of serum of mice infected
with gene-deleted viruses display differences in neutralization activity. Bars
represent the mean and SD of endpoint titer and percent of neutralization for
individual animals in each experimental group.
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Materials and methods
Viruses, cells and animals
The parental MPXV strain Congo-2003-358 (MPXV/Congo) was
provided by Dr. Inger K. Damon (Centers for Disease Control,
Atlanta, GA, USA). All studies were conducted under BSL-3 condi-
tions at the USGS, National Wildlife Health Center – Madison
(NWHC, Madison, WI, USA). Experimental protocols were
approved by the NWHC biosafety committee. Virus titration and
propagation were conducted in African green monkey kidney
epithelial cells (Vero and BS-C-1) and human alveolar epithelial
cells (A549) obtained from American Type Culture Collection
(ATCC: CCL81, CCL-26 and CCL-185). Virus titers were calculated
by plaque assays and were performed using 12-well plates of Vero
cells incubated under semisolid overlay (cell culture medium
containing 2% FBS and 1.5% carboxymethylcellulose) for 72 h. All
cells were maintained with the ATCC recommended culture media
at 37 1C and 5% CO2. Plates were ﬁxed and plaques were visualized
by staining with 0.1% crystal violet in 10% neutral buffered
formalin. Mouse studies were conducted using 4 week-old female
CAST/EiJ mice purchased from the Jackson Laboratories
(Bar Harbor, ME). Animals were housed in cages with an aerosol
ﬁlter and standard husbandry practices were performed in
accordance with NWHC animal care and IACUC guidelines (Proto-
col # EP090616A). Virus titers were veriﬁed before and after the
experiments to ensure the accuracy of the doses administered.
Bioinformatics analysis and generation of recombinant MPXVs
Genomic regions (R) in MPXV were identiﬁed by multiple
genome alignments and sequence analysis using MAUVE and
DAMBE software packages (Fig. 1) (Darling et al., 2010; Xia,
2013). MAUVE produces genomic alignments from which ortho-
logous and divergent regions can be identiﬁed. These regions are
then automatically categorized based on the degree of change, and
ﬁne-scale analyses of nucleotide and amino acid changes of
individual genes were performed with DAMBE.
To generate mutant deleted viruses, transfer plasmids contain-
ing the luciferase gene marker (Lucþ), the guanosine phosphor-
ibosyl transferase (GPT) selection gene under the control of the
synthetic early late promoter (SE/L), and the ﬂanking sequences of
target genomic regions were constructed using methods pre-
viously described (Osorio et al., 2009) (Fig. 2). Brieﬂy, for MPXV
with R1 deleted (MPXV-ΔR1), sequences for the left (721 bp) and
right (719 bp) ﬂanks were PCR ampliﬁed and cloned into transfer
plasmids. For MPXV with R2 deleted (MPXV-ΔR2), sequences for
the left (954 bp) and right (866 bp) ﬂanks were PCR ampliﬁed and
Fig. 7. Hematoxylin and eosin stained spleens and lungs of infected and control CAST/EiJ mice (25 ). Spleens of animals infected with parental MPXV-Congo/Lucþ
(A) displayed severe lymphoid necrosis with loss of much of the germinal centers and replacement with adipose tissue. Spleens of animals infected with the double deletion,
MPXV-ΔR1/R2 (C), have widened germinal centers, indicative of lymphoid hyperplasia. Spleens of uninfected mice display smaller germinal centers with discrete separation
of white pulp and red pulp (E). Lungs of mice infected with MPX-Congo/Lucþ (B) had severe multifocal lymphocytic pneumonia with necrosis and copious ﬁbrin present in
the bronchioles and alveoli. Lungs of MPXV-ΔRl/R2, had sparse lymphocytic inﬁltrates (D). Lung of an uninfected control mouse (F).
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cloned. For the construction and selection of MPXV with simulta-
neous deletion of both genomic regions (MPXV-ΔR1/R2), we used
MPXV-ΔR1 as the parental virus and deleted R2 using a transfer
plasmid containing cerulean ﬂuorescent protein gene (CFP) as a
selection marker with the same ﬂanking sequences of the indivi-
dual R2 deletion. Table 1 shows the composition, genomic loca-
tion, and reported function of deleted genes in each genomic
region. Sequencing, PCR, and luciferase assays showed that the
gene-deleted viruses contained the intended deletions and the
luciferase gene marker (data not shown). Sequences and binding
sites of primers used in this study are listed in Table 2.
Kinetics of replication and plaque size phenotype
Twelve-well plates containing semi-conﬂuent Vero and A549
cells were infected with each virus in duplicate, with a multiplicity
of infection (MOI) of 5 plaque forming units (PFU) per cell. Cells
were incubated for 45 min for virus adsorption, infection media
was removed, and cells were washed twice with 1 phosphate
buffered saline (PBS). Fresh media was added and virus was
harvested at 0, 4, 8, 12, 24, 48, and 72 h post-infection (pi) and
stored at 80 1C. After three cycles of freezing and thawing,
samples were sonicated and virus titers were determined by 50%
tissue culture infective dose (TCID50/ml) as described elsewhere
(Falendysz et al., 2014). Plaque morphology was analyzed by
performing plaque assays as described in the previous section.
Plaque sizes (n440) were measured using ImagePro Plus 3.1 soft-
ware (Media Cybernetics, USA) and an ImmunoSpot microscope
(Cellular Technology Ltd, USA). Differences in virus titers and
plaque diameters were plotted using GraphPad Prism software
(La Jolla, CA). Student's t-test method was used to determine
statistical signiﬁcance, with alpha¼1%.
Inoculation of animals and sample collection
CAST/EiJ mice, which have been shown to be highly susceptible
to MPXV infection (Americo et al., 2010; Earl et al., 2012), were
used to characterize the effect of deletion of target genomic
regions on MPXV pathogenicity. Groups (n¼3–4) of 4-week-old
CAST/EiJ mice were inoculated intranasally (IN) with 106 PFU/
0.01 ml of either MPXV-ΔR1, MPXV-ΔR2, or MPXV-ΔR1/R2.
MPXV-Congo/Lucþ (same dose and route) served as a positive
control. A group of two additional animals were inoculated with
PBS as a negative control. We previously demonstrated that the
insertion of the luciferase gene (Lucþ) does not affect viral
replication when compared to wild type MPXV-Congo (Osorio
et al., 2009). Daily observation of food consumption, activity level,
and general appearance was recorded. Viral replication, tissue
tropism, and persistence were monitored by in vivo imaging.
Bioluminescent imaging and weighing were performed on days
2, 4, 6, 8, 10, 13, 17, and 20 pi. Images were acquired with an IVIS
200 series in vivo imager (Perkin-Elmer, Waltham, MA). Addition-
ally, serum samples were collected prior to infection and at days
13 and 20 pi to test for antibodies. Animals that lost 20% of their
starting weight were euthanized in accordance with institutional
animal care and use protocols. After death, lungs and spleen were
removed; a portion of each organwas ﬁxed in 10% neutral buffered
formalin and remaining tissue was frozen at 80 1C for later PCR
and viral titration.
Region of interest (ROI) analysis was performed using Living
Image 4.2 (Perkin-Elmer, Waltham, MA) of rectangular ROIs that
enclosed ventral views of individual animals. Total luminescence
was estimated as mean average radiance [p/s/cm²/sr] of ventral
views of individual mice and plotted with the time of infection.
Mean percent of weight change for each experimental group was
calculated and plotted over time. Differences in luminescence and
weight change were compiled in Microsoft Excel ﬁles and ana-
lyzed using GraphPad Prism software. Student's t-test corrected
for multiple comparisons with the Sidak–Bonferroni method was
used to determine statistical signiﬁcance, with alpha¼1%.
Real-time PCR and viral titration
To verify presence or absence of virus and quantify tissue titers
in infected mice, tissues collected at the time of death or
euthanasia were evaluated by real-time PCR and cell culture
isolation assays. Tissue samples were homogenized using a Bullet
Blender Storm bead homogenizer (Next Advance, Averill Park, NY)
according to tissue-speciﬁc protocols (Next Advance, 2012). Total
DNA was extracted from aliquots of 100 μl of tissue slurry using
Quick-gDNA™ kit (ZYMO RESEARCH, Irvine, CA). Homogenized
tissues were tested for the presence of viral DNA using real-time
PCR to amplify the E9L gene of orthopoxviruses as described
elsewhere (Li et al., 2010) with minor modiﬁcations. The remain-
ing aliquots (100 μl) of the tissue slurry were evaluated for virus
isolation and titration as described above.
Table 2
List of primer sequences used in construction, selection and puriﬁcation of gene-deleted MPXV viruses.
Regions and Plasmids Primers Sequence 50-30 PCR product (bp) Description
Region R1 P1-F ttataggaacgcgtacgagaa 721 Left ﬂank ΔR1
P1-R actaaaaatttgtaagccgtatat
P2-F tacccataaacaatataaatccag 719 Right ﬂank ΔR1
P2-R attaaactttagacgagatgcg
P3-F tgtgtcggtagacgataccg 290 ΔR1 conﬁrmation
P3-R caactacaatgtagactttaagtgc
P4-F caccacaagaacacacgaacg 310 ΔR1 conﬁrmation
P4-R ttcaggcgcatcagtattcg
Region R2 P5-F atgaaaacgatttccgttgttac 594 Left ﬂank ΔR2
P5-R tcacggtagcaatttatggaact
P6-F atggatgaagatacgcgactatc 866 Right ﬂank ΔR2
P6-R attggatccttattactgctatcc
P7-F agatgaggtccctgattatagtcc 259 ΔR2 conﬁrmation
P7-R tcggtgataataaagtcatgtgg
P8-F ccacatgactttattatcaccga 366 ΔR2 conﬁrmation
P8-R accttttgtagacattacggtcg
pGPTlucþ P9-F gagcacggaaagacgatgac 500 Conﬁrmation of luciferase gene insertion
P9-R tcgttattgatgacctggtgg
pI2-mCFP P10-F atggtgagcaagggcgaggagc 720 Conﬁrmation of ﬂuorescence gene insertion
P10-R ttacttgtacagctcgtgcatgc
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Measure of antibody responses
Enzyme-linked immunosorbent assay (ELISA) and neutralizing
activity assays were used to evaluate serum of mice infected with
recombinant MPXVs. For measuring total IgG titers, individual
serum samples collected at days 13 and 20 pi were tested as
described elsewhere (Hutson et al., 2007). Brieﬂy, 96-well micro-
titer plates were coated with crude viral antigen (lysate of Vero
cells infected with VACV) and uninfected Vero cell lysate. Plates
were blocked (PBS, 0.05% Tween-20, 5% dried skim milk, 2%
normal goat serum, and 2% bovine serum albumin) for 1 h. Six
serial 2-fold dilutions (1:50, 1:100, 1:200, 1:400, 1:800 and
1:1600) of serum were incubated in duplicate for 1 h at 37 1C.
Plates were washed four times (PBS plus 0.05% Tween-20), and
conjugated secondary antibody (Pierce ImmunoPure© Protein A/G
Peroxidase conjugated) was added and incubated for 1 h at 37 1C.
Peroxidase substrate was added and incubated for 15 min, at
which point stop solution was added to cease the reaction before
quantiﬁcation. Absorbance was read on an ELISA reader at 450 nm.
Samples were considered positive if the test absorbance was above
the estimated cut-off value (COV), which was deﬁned as three
standard deviations above the mean of the negative controls. A
luciferase based MPXV serum neutralization assay was used to test
neutralizing antibody activity as described elsewhere (Liu et al.,
2012). Brieﬂy, samples were incubated in duplicate on 96-well
plates for 1 h at 37 1C with 100 PFU/well of MPXV-Congo/Lucþ
and six serial 2-fold dilutions (1:40, 1:80, 1:160, 1:340, 1:680 and
1:1280) of serum. Then, cells were incubated (virus and serum
dilutions) for 24 h, lysed, and reduction in luminescence was
measured using a plate luminometer (VICTORs Light 1420 lumi-
nescence counter, Perkin-Elmer, Waltham, MA, USA). To ensure
the speciﬁcity of the assay conditions, positive and negative sera
were used to normalize the ELISA titers and luminescence read-
ings. All reported values represent the average of duplicate
samples. Serum samples of CAST/EiJ mice infected with a sublethal
dose (102 PFU) of parental MPXV-Congo/Lucþ from previous
studies were used as positive controls, and serum from an
uninfected mouse was utilized as a negative control.
Histopathology
After death or euthanasia, necropsy was performed on all
groups to evaluate tissue pathology. Fixed tissue sections from
the lung and spleen of control and infected animals were stained
with hematoxylin and eosin (H&E) and histological changes were
assessed.
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